Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation.


Journal Article

This article demonstrates a case of a lung adenocarcinoma patient in stage IV harboring an epidermal growth factor receptor (EGFR) 19 exon deletion mutation treated with 500 mg/m2 pemetrexed and 75 mg/m2 cisplatin on day 1, sequenced with 250 mg gefitinib on prescription on days 4-28 for six cycles as first-line, then by gefitinib combined with pemetrexed as maintenance therapy. The patient achieved a partial response. Performance status increased from grade 2 to 1. The progression-free survival period was 17 months. Overall survival is now over three years. Side effects of grade two liver dysfunction and dermal toxicity were tolerable. Combined gefitinib with platinum-based chemotherapy as first-line treatment probably benefits non-small cell cancer patients in stage IV harboring sensitive EGFR gene mutations with a better local control rate, longer survival, and tolerable side effects.

Full Text

Duke Authors

Cited Authors

  • Huang, A; Li, R; Zhao, J; Wang, X; Jin, B; Niu, Y; Zhang, J; Jiang, L; Han, B

Published Date

  • September 2016

Published In

Volume / Issue

  • 7 / 5

Start / End Page

  • 614 - 618

PubMed ID

  • 27766772

Pubmed Central ID

  • 27766772

Electronic International Standard Serial Number (EISSN)

  • 1759-7714

Digital Object Identifier (DOI)

  • 10.1111/1759-7714.12364


  • eng

Conference Location

  • Singapore